Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

[1]  E. Estey,et al.  Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Labopin,et al.  Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT , 2014, Bone Marrow Transplantation.

[3]  M. Caligiuri,et al.  Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. Estey,et al.  Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. , 2013, Blood.

[5]  P. Armand,et al.  Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  P. Armand,et al.  Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  M. Labopin,et al.  Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients , 2012, Journal of internal medicine.

[8]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[9]  B. Andersson,et al.  Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  M. Mohty,et al.  Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. , 2011, Cancer control : journal of the Moffitt Cancer Center.

[11]  E. Estey,et al.  Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Perkins,et al.  Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia , 2010, Journal of hematology & oncology.

[13]  M. Maris,et al.  Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Labopin,et al.  Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Zimmerman,et al.  Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Thall,et al.  Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. , 2004, Blood.

[17]  R. Brookmeyer,et al.  Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. , 1983, The New England journal of medicine.

[18]  E. Scott,et al.  Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia. , 1980, The New England journal of medicine.

[19]  A. Nagler,et al.  Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity , 2006, Leukemia.